VERTEX PHARMACEUTICALS INC / MA Research and Development Expense
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Research and Development Expense of $603.10 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-06.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2022-05-06
- VERTEX PHARMACEUTICALS INC / MA research and development expense for the quarter ending 2022-03-31 was $603.10M, a 32.26% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA research and development expense for the quarter ending 2021-12-31 was $694.29M, a 48.80% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA research and development expense for the quarter ending 2021-09-30 was $493.75M, a 0.05% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA research and development expense for the quarter ending 2021-06-30 was $1.41B, a 234.28% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA research and development expense for fiscal 2021 was $3.05B, a 66.77% increase from fiscal 2020.
- VERTEX PHARMACEUTICALS INC / MA research and development expense for fiscal 2020 was $1.83B, a 4.27% increase from fiscal 2019.
- VERTEX PHARMACEUTICALS INC / MA research and development expense for fiscal 2019 was $1.75B, a 23.86% increase from fiscal 2018.
- VERTEX PHARMACEUTICALS INC / MA research and development expense for fiscal 2018 was $1.42B, a 6.93% increase from fiscal 2017.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2022-03-31 | $603.10M 10-Q · filed 2022-05-06 | $1.30B derived: sum of 2 quarters · filed 2022-05-06 | $1.79B derived: sum of 3 quarters · filed 2022-05-06 | $3.20B derived: sum of 4 quarters · filed 2022-05-06 | ||||
| 2021-12-31 | $694.29M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $1.19B derived: sum of 2 quarters · filed 2022-02-09 | $2.60B derived: sum of 3 quarters · filed 2022-02-09 | $3.05B 10-K · filed 2022-02-09 | ||||
| 2021-09-30 | $493.75M 10-Q · filed 2021-11-03 | $1.90B derived: sum of 2 quarters · filed 2021-11-03 | $2.36B 10-Q · filed 2021-11-03 | $2.82B derived: sum of 4 quarters · filed 2022-05-06 | ||||
| 2021-06-30 | $1.41B 10-Q · filed 2021-07-30 | $1.86B 10-Q · filed 2021-07-30 | $2.33B derived: sum of 3 quarters · filed 2022-05-06 | $2.82B derived: sum of 4 quarters · filed 2022-05-06 | ||||
| 2021-03-31 | $456.00M 10-Q · filed 2022-05-06 | $455.97M 10-Q · filed 2021-04-30 | $922.58M derived: sum of 2 quarters · filed 2022-05-06 | $1.42B derived: sum of 3 quarters · filed 2022-05-06 | $1.84B derived: sum of 4 quarters · filed 2022-05-06 | |||
| 2020-12-31 | $466.58M 10-K · filed 2021-02-11 | $960.08M derived: sum of 2 quarters · filed 2021-11-03 | $1.38B derived: sum of 3 quarters · filed 2021-11-03 | $1.83B 10-K · filed 2022-02-09 | $1.83B 10-K · filed 2021-02-11 | |||
| 2020-09-30 | $493.50M 10-Q · filed 2021-11-03 | $914.42M derived: sum of 2 quarters · filed 2021-11-03 | $1.36B 10-Q · filed 2021-11-03 | $1.84B derived: sum of 4 quarters · filed 2021-11-03 | ||||
| 2020-06-30 | $420.93M 10-Q · filed 2021-07-30 | $869.46M 10-Q · filed 2021-07-30 | $1.35B derived: sum of 3 quarters · filed 2021-07-30 | $1.91B derived: sum of 4 quarters · filed 2021-07-30 | ||||
| 2020-03-31 | $448.53M 10-Q · filed 2021-04-30 | $928.54M derived: sum of 2 quarters · filed 2021-04-30 | $1.48B derived: sum of 3 quarters · filed 2021-04-30 | $1.86B derived: sum of 4 quarters · filed 2021-04-30 | ||||
| 2019-12-31 | $480.01M 10-K · filed 2021-02-11 | $1.04B derived: sum of 2 quarters · filed 2021-02-11 | $1.42B derived: sum of 3 quarters · filed 2021-02-11 | $1.75B 10-K · filed 2022-02-09 | $1.75B 10-K · filed 2020-02-13 | |||
| 2019-09-30 | $555.95M 10-K · filed 2021-02-11 | $935.04M derived: sum of 2 quarters · filed 2021-02-11 | $1.27B 10-Q · filed 2020-10-30 | $1.71B derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-06-30 | $379.09M 10-K · filed 2021-02-11 | $718.58M 10-Q · filed 2020-07-31 | $1.16B derived: sum of 3 quarters · filed 2021-02-11 | $1.49B derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-03-31 | $339.49M 10-K · filed 2021-02-11 | $777.37M derived: sum of 2 quarters · filed 2021-02-11 | $1.11B derived: sum of 3 quarters · filed 2021-02-11 | $1.45B derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2018-12-31 | $437.88M 10-K · filed 2020-02-13 | $768.39M derived: sum of 2 quarters · filed 2020-02-13 | $1.11B derived: sum of 3 quarters · filed 2020-02-13 | $1.42B 10-K · filed 2021-02-11 | ||||
| 2018-09-30 | $330.51M 10-K · filed 2020-02-13 | $668.04M derived: sum of 2 quarters · filed 2020-02-13 | $978.60M 10-Q · filed 2019-10-31 | $1.29B derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2018-06-30 | $337.53M 10-K · filed 2020-02-13 | $648.09M 10-Q · filed 2019-08-01 | $954.75M derived: sum of 3 quarters · filed 2020-02-13 | $1.41B derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2018-03-31 | $310.55M 10-K · filed 2020-02-13 | $617.22M derived: sum of 2 quarters · filed 2020-02-13 | $1.07B derived: sum of 3 quarters · filed 2020-02-13 | $1.36B derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2017-12-31 | $306.66M 10-K · filed 2019-02-13 | $761.61M derived: sum of 2 quarters · filed 2019-02-13 | $1.05B derived: sum of 3 quarters · filed 2019-02-13 | $1.32B 10-K · filed 2020-02-13 | ||||
| 2017-09-30 | $454.95M 10-K · filed 2019-02-13 | $744.40M derived: sum of 2 quarters · filed 2019-02-13 | $1.02B 10-Q · filed 2018-10-25 | $1.27B derived: sum of 4 quarters · filed 2019-02-13 | ||||
| 2017-06-30 | $289.45M 10-K · filed 2019-02-13 | $563.01M 10-Q · filed 2018-07-26 | $811.47M derived: sum of 3 quarters · filed 2019-02-13 | $1.08B derived: sum of 4 quarters · filed 2019-02-13 | ||||
| 2017-03-31 | $273.56M 10-K · filed 2019-02-13 | $522.01M derived: sum of 2 quarters · filed 2019-02-13 | $794.38M derived: sum of 3 quarters · filed 2019-02-13 | $1.07B derived: sum of 4 quarters · filed 2019-02-13 | ||||
| 2016-12-31 | $248.45M 10-K · filed 2018-02-15 | $520.82M derived: sum of 2 quarters · filed 2018-02-15 | $791.83M derived: sum of 3 quarters · filed 2018-02-15 | $1.05B 10-K · filed 2019-02-13 | ||||
| 2016-09-30 | $272.37M 10-K · filed 2018-02-15 | $543.38M derived: sum of 2 quarters · filed 2018-02-15 | $799.24M 10-Q · filed 2017-10-30 | $1.11B derived: sum of 4 quarters · filed 2018-02-15 | ||||
| 2016-06-30 | $271.01M 10-K · filed 2018-02-15 | $526.87M 10-Q · filed 2017-07-28 | $837.05M derived: sum of 3 quarters · filed 2018-02-15 | $1.08B derived: sum of 4 quarters · filed 2018-02-15 | ||||
| 2016-03-31 | $255.86M 10-K · filed 2018-02-15 | $566.04M derived: sum of 2 quarters · filed 2018-02-15 | $812.33M derived: sum of 3 quarters · filed 2018-02-15 | $1.04B derived: sum of 4 quarters · filed 2018-02-15 | ||||
| 2015-12-31 | $310.18M 10-K · filed 2017-02-23 | $556.47M derived: sum of 2 quarters · filed 2017-02-23 | $780.32M derived: sum of 3 quarters · filed 2017-02-23 | $995.92M 10-K · filed 2018-02-15 | ||||
| 2015-09-30 | $246.28M 10-K · filed 2017-02-23 | $470.14M derived: sum of 2 quarters · filed 2017-02-23 | $685.74M 10-Q · filed 2016-10-31 | $887.20M derived: sum of 4 quarters · filed 2017-02-23 | ||||
| 2015-06-30 | $223.86M 10-K · filed 2017-02-23 | $439.46M 10-Q · filed 2016-08-01 | $640.92M derived: sum of 3 quarters · filed 2017-02-23 | $831.86M derived: sum of 4 quarters · filed 2017-02-23 | ||||
| 2015-03-31 | $215.60M 10-K · filed 2017-02-23 | $417.06M derived: sum of 2 quarters · filed 2017-02-23 | $608.00M derived: sum of 3 quarters · filed 2017-02-23 | $832.49M derived: sum of 4 quarters · filed 2017-02-23 | ||||
| 2014-12-31 | $201.46M 10-K · filed 2016-02-16 | $392.40M derived: sum of 2 quarters · filed 2016-02-16 | $616.89M derived: sum of 3 quarters · filed 2016-02-16 | $855.51M 10-K · filed 2017-02-23 | ||||
| 2014-09-30 | $190.94M 10-K · filed 2016-02-16 | $415.43M derived: sum of 2 quarters · filed 2016-02-16 | $654.04M 10-Q · filed 2015-10-30 | $892.50M derived: sum of 4 quarters · filed 2016-02-16 | ||||
| 2014-06-30 | $224.49M 10-K · filed 2016-02-16 | $224.78M 10-Q · filed 2014-07-31 | $463.10M 10-Q · filed 2015-08-04 | $463.74M 10-Q · filed 2014-07-31 | $701.57M derived: sum of 3 quarters · filed 2016-02-16 | $921.01M derived: sum of 4 quarters · filed 2016-02-16 | ||
| 2014-03-31 | $238.62M 10-K · filed 2016-02-16 | $238.96M 10-Q · filed 2014-05-05 | $477.08M derived: sum of 2 quarters · filed 2016-02-16 | $696.52M derived: sum of 3 quarters · filed 2016-02-16 | $910.51M derived: sum of 4 quarters · filed 2016-02-16 | |||
| 2013-12-31 | $238.46M 10-K · filed 2015-02-13 | $249.61M 10-K · filed 2014-02-11 | $457.90M derived: sum of 2 quarters · filed 2015-02-13 | $671.90M derived: sum of 3 quarters · filed 2015-02-13 | $882.10M 10-K · filed 2016-02-16 | $918.78M 10-K · filed 2014-02-11 | ||
| 2013-09-30 | $219.44M 10-K · filed 2015-02-13 | $228.62M 10-Q · filed 2013-11-07 | $433.44M derived: sum of 2 quarters · filed 2015-02-13 | $643.64M 10-Q · filed 2014-11-06 | $669.17M 10-Q · filed 2013-11-07 | $856.75M derived: sum of 4 quarters · filed 2015-02-13 | ||
| 2013-06-30 | $213.99M 10-K · filed 2015-02-13 | $222.46M 10-Q · filed 2013-08-02 | $440.55M 10-Q · filed 2014-07-31 | $637.30M derived: sum of 3 quarters · filed 2015-02-13 | $837.46M derived: sum of 4 quarters · filed 2015-02-13 | |||
| 2013-03-31 | $210.20M 10-K · filed 2015-02-13 | $218.09M 10-Q · filed 2013-05-08 | $423.31M derived: sum of 2 quarters · filed 2015-02-13 | $623.47M derived: sum of 3 quarters · filed 2015-02-13 | $820.01M derived: sum of 4 quarters · filed 2015-02-13 | |||
| 2012-12-31 | $213.11M 10-K · filed 2014-02-11 | $413.27M derived: sum of 2 quarters · filed 2014-02-11 | $609.81M derived: sum of 3 quarters · filed 2014-02-11 | $765.90M 10-K · filed 2015-02-13 | $806.18M 10-K · filed 2013-03-01 | |||
| 2012-09-30 | $200.16M 10-K · filed 2014-02-11 | $396.70M derived: sum of 2 quarters · filed 2014-02-11 | $593.08M 10-Q · filed 2013-11-07 | $779.51M derived: sum of 4 quarters · filed 2014-02-11 | ||||
| 2012-06-30 | $196.54M 10-K · filed 2014-02-11 | $392.92M 10-Q · filed 2013-08-02 | $579.35M derived: sum of 3 quarters · filed 2014-02-11 | $768.40M derived: sum of 4 quarters · filed 2014-02-11 | ||||
| 2012-03-31 | $196.37M 10-K · filed 2014-02-11 | $382.81M derived: sum of 2 quarters · filed 2014-02-11 | $571.86M derived: sum of 3 quarters · filed 2014-02-11 | $745.47M derived: sum of 4 quarters · filed 2014-02-11 | ||||
| 2011-12-31 | $186.44M 10-K · filed 2013-03-01 | $375.49M derived: sum of 2 quarters · filed 2013-03-01 | $549.09M derived: sum of 3 quarters · filed 2013-03-01 | $707.71M 10-K · filed 2014-02-11 | ||||
| 2011-09-30 | $189.05M 10-K · filed 2013-03-01 | $362.66M derived: sum of 2 quarters · filed 2013-03-01 | $521.27M 10-Q · filed 2012-11-06 | $690.16M derived: sum of 4 quarters · filed 2013-03-01 | ||||
| 2011-06-30 | $173.60M 10-K · filed 2013-03-01 | $332.22M 10-Q · filed 2012-08-08 | $501.10M derived: sum of 3 quarters · filed 2013-03-01 | $671.54M derived: sum of 4 quarters · filed 2013-03-01 | ||||
| 2011-03-31 | $158.61M 10-K · filed 2013-03-01 | $327.50M derived: sum of 2 quarters · filed 2013-03-01 | $497.93M derived: sum of 3 quarters · filed 2013-03-01 | $653.02M derived: sum of 4 quarters · filed 2013-03-01 | ||||
| 2010-12-31 | $168.89M 10-K · filed 2012-02-22 | $339.32M derived: sum of 2 quarters · filed 2012-02-22 | $494.40M derived: sum of 3 quarters · filed 2012-02-22 | $637.42M 10-K · filed 2013-03-01 | ||||
| 2010-09-30 | $170.43M 10-K · filed 2012-02-22 | $325.52M derived: sum of 2 quarters · filed 2012-02-22 | $468.53M 10-Q · filed 2011-11-03 | $603.76M derived: sum of 4 quarters · filed 2012-02-22 | ||||
| 2010-06-30 | $155.08M 10-K · filed 2012-02-22 | $298.09M 10-Q · filed 2011-08-09 | $433.32M derived: sum of 3 quarters · filed 2012-02-22 | $565.46M derived: sum of 4 quarters · filed 2012-02-22 | ||||
| 2010-03-31 | $143.01M 10-K · filed 2012-02-22 | $278.24M derived: sum of 2 quarters · filed 2012-02-22 | $410.37M derived: sum of 3 quarters · filed 2012-02-22 | $549.71M derived: sum of 4 quarters · filed 2012-02-22 | ||||
| 2009-12-31 | $135.23M 10-K · filed 2011-02-17 | $267.36M derived: sum of 2 quarters · filed 2011-02-17 | $406.69M derived: sum of 3 quarters · filed 2011-02-17 | $550.27M 10-K · filed 2012-02-22 | ||||
| 2009-09-30 | $132.13M 10-K · filed 2011-02-17 | $271.46M derived: sum of 2 quarters · filed 2011-02-17 | $415.04M 10-Q · filed 2010-10-28 | |||||
| 2009-06-30 | $139.33M 10-K · filed 2011-02-17 | $282.91M 10-Q · filed 2010-08-03 | ||||||
| 2009-03-31 | $143.58M 10-K · filed 2011-02-17 | |||||||
| 2008-12-31 | $516.91M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |